leisure time -WSS

leisure time

author：fashion 2025-09-03 03:24:55 - browse：6

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Studies point to risks of excluding people with obesity from drug trials

WSS

Scientists inch closer to single

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Vertex non

Beam Therapeutics to lay off 20% of its staff, re

The high personal cost of affirmative action for Black doctors

Solve the antibiotic resistance crisis with preventive drugs

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

FDA warns J&J's Abiomed: We will regulate your software

Alkermes shareholders re

Eli Lilly expects to double planned employment in Boston center

Medicare details structure of new drug price negotiation program

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

New air purifier tech could be key to improving indoor air quality

5 important ways Henrietta Lacks changed medical science

Walensky prepares to leave CDC — and Congress — behind

FDA warns J&J's Abiomed: We will regulate your software

leisure time

FDA warns J&J's Abiomed: We will regulate your software

Mega Millions pot grows to $1.25 billion after no winner

Will Ozempic

NIH confirmation hearing shows politicization of research

Why health workers in Gaza are injured or die at high rates

Medicare reduced heart disease by changing how it pays doctors

focus

entertainment

focus

focus